文献速递淋巴瘤

外周T细胞淋巴瘤:所有患者都是高危吗?

Peripheral T-cell lymphoma: are all patients high risk?
PubMed 文献 · Blood · 2024-01-01

外周T细胞淋巴瘤(PTCL)约占非霍奇金淋巴瘤的10%,多数患者预后差,大型注册研究显示5年总生存率约30%至40%。本综述总结了常见亚型的注册结局,描述了已验证的临床预后指数,并重点介绍新兴预后工具,包括分子生物标志物、影像学指标和微小残留病(MRD)动态监测。

要点

  • PTCL异质性强,多数患者采用环磷酰胺、多柔比星、长春新碱和泼尼松为基础的方案治疗。
  • 大型注册研究一致显示PTCL患者5年总生存率约30%至40%。
  • 正电子发射断层扫描-计算机断层扫描和MRD监测有望实现动态风险分层。

核心结论

  • 随着对PTCL生物学异质性认识的提高和PTCL特异性治疗的发展,风险分层已成为更相关的问题。

研究设计与样本

  • 本综述首先总结常见PTCL亚型的注册数据,随后描述已验证的临床预后指数并重点介绍新兴预后工具。

主要发现

  • 大型注册研究一致显示PTCL患者5年总生存率约30%至40%。
  • 综述总结了PTCL非特指型、伴血管免疫母细胞性T细胞淋巴瘤的淋巴结T滤泡辅助细胞淋巴瘤和间变性大细胞淋巴瘤的注册结局。

关键数值与推荐

  • 正电子发射断层扫描-计算机断层扫描和微小残留病(MRD)监测有望用于动态风险分层。
  • 新兴预后工具包括新型分子生物标志物、基于影像学的指标和MRD动态变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of mature T-cell neoplasms that represent ∼10% of all non-Hodgkin lymphoma. Outcomes for the majority of patients with PTCL are poor, and treatment approaches have been relatively uniform using cyclophosphamide, doxorubicin, vincristine, and prednisone-based therapy. For example, large registry studies consistently demonstrate 5-year overall survival of ∼30% to 40%. However, as our understanding of the biology underpinning the heterogeneity of PTCL improves and as treatments specifically for PTCL are developed, risk stratification has become a more relevant question. Tools including positron emission tomography-computed tomography and minimal residual disease (MRD) monitoring offer the potential for dynamic risk stratification. In this review, we first summarize registry data describing outcomes in the most common subtypes of PTCL: PTCL not otherwise specified, nodal T-follicular helper cell lymphoma including angioimmunoblastic T-cell lymphoma, and anaplastic large cell lymphoma. We describe current clinically based prognostic indices validated for PTCL and highlight emerging tools for prognostication including novel molecular biomarkers, imaging-based metrics, and MRD dynamics.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Shea L, Mehta-Shah N. Peripheral T-cell lymphoma: are all patients high risk? Blood. 2024. PMID: 38142400. doi:10.1182/blood.2023020912

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。